CIAM
CORT icon

Caitong International Asset Management’s Corcept Therapeutics CORT Stock Holding History

Caitong International Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6K Sell
362
-251,270
-100% -$9.4M ﹤0.01% 1038
2025
Q4 		$8.76M Buy
+251,632
New +$19.8M 2.15% 9
2025
Q2 		– Sell
-37,588
Closed -$4.29M – 2082
2025
Q1 		$4.29M Buy
+37,588
New +$2.29M 3.19% 4

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Caitong International Asset Management's CORT Position: Q1 2026 in Review

Caitong International Asset Management reduced its Corcept Therapeutics (CORT) stake by 100% in Q1 2026, selling an estimated $9.4M and leaving 362 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1038.

Caitong International Asset Management first reported a position in CORT in Q1 2025 and has held it in 3 quarters since. The position peaked at $8.76M in Q4 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Caitong International Asset Management held 362 shares of Corcept Therapeutics worth $14.6K as of Q1 2026.
  • Caitong International Asset Management sold 251,270 Corcept Therapeutics shares in Q1 2026, an estimated $9.4M.
  • Corcept Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1038 holding.
  • Caitong International Asset Management first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's Corcept Therapeutics position peaked at $8.76M in Q4 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.